Innoviva (INVA) Competitors $19.55 +0.18 (+0.94%) Closing price 03:59 PM EasternExtended Trading$19.55 0.00 (-0.01%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock INVA vs. ALKS, LGND, FOLD, BCRX, MNKD, CLDX, NVAX, DVAX, OPK, and GERNShould you be buying Innoviva stock or one of its competitors? The main competitors of Innoviva include Alkermes (ALKS), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), BioCryst Pharmaceuticals (BCRX), MannKind (MNKD), Celldex Therapeutics (CLDX), Novavax (NVAX), Dynavax Technologies (DVAX), OPKO Health (OPK), and Geron (GERN). These companies are all part of the "biotechnology" industry. Innoviva vs. Its Competitors Alkermes Ligand Pharmaceuticals Amicus Therapeutics BioCryst Pharmaceuticals MannKind Celldex Therapeutics Novavax Dynavax Technologies OPKO Health Geron Alkermes (NASDAQ:ALKS) and Innoviva (NASDAQ:INVA) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends. Does the media favor ALKS or INVA? In the previous week, Alkermes had 17 more articles in the media than Innoviva. MarketBeat recorded 26 mentions for Alkermes and 9 mentions for Innoviva. Innoviva's average media sentiment score of 1.22 beat Alkermes' score of 0.58 indicating that Innoviva is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alkermes 8 Very Positive mention(s) 2 Positive mention(s) 11 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Innoviva 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals hold more shares of ALKS or INVA? 95.2% of Alkermes shares are held by institutional investors. Comparatively, 99.1% of Innoviva shares are held by institutional investors. 4.4% of Alkermes shares are held by company insiders. Comparatively, 2.3% of Innoviva shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Is ALKS or INVA more profitable? Alkermes has a net margin of 23.15% compared to Innoviva's net margin of 10.44%. Alkermes' return on equity of 24.86% beat Innoviva's return on equity.Company Net Margins Return on Equity Return on Assets Alkermes23.15% 24.86% 17.14% Innoviva 10.44%18.67%9.92% Which has stronger earnings and valuation, ALKS or INVA? Alkermes has higher revenue and earnings than Innoviva. Alkermes is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlkermes$1.51B2.91$367.07M$2.0812.76Innoviva$358.71M3.43$23.39M$0.3163.07 Do analysts prefer ALKS or INVA? Alkermes currently has a consensus price target of $41.85, suggesting a potential upside of 57.65%. Innoviva has a consensus price target of $42.75, suggesting a potential upside of 118.65%. Given Innoviva's stronger consensus rating and higher possible upside, analysts clearly believe Innoviva is more favorable than Alkermes.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alkermes 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 2.92Innoviva 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, ALKS or INVA? Alkermes has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, Innoviva has a beta of 0.47, suggesting that its stock price is 53% less volatile than the S&P 500. SummaryAlkermes beats Innoviva on 11 of the 17 factors compared between the two stocks. Get Innoviva News Delivered to You Automatically Sign up to receive the latest news and ratings for INVA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INVA vs. The Competition Export to ExcelMetricInnovivaLarge Cap Pharma IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.23B$252.33B$5.75B$10.27BDividend YieldN/A2.72%5.72%4.60%P/E Ratio63.0730.4275.1726.41Price / Sales3.434.67455.9688.49Price / Cash5.6513.6625.8129.91Price / Book1.7718.5913.256.28Net Income$23.39M$8.49B$3.29B$270.38M7 Day Performance-4.44%-1.30%0.76%2.79%1 Month Performance-6.54%0.17%4.63%6.00%1 Year Performance-1.30%-9.83%73.44%25.97% Innoviva Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INVAInnoviva4.8384 of 5 stars$19.55+0.9%$42.75+118.6%-2.2%$1.23B$358.71M63.07100Positive NewsAnalyst DowngradeShort Interest ↓ALKSAlkermes4.5436 of 5 stars$28.45-5.0%$41.31+45.2%-2.5%$4.94B$1.56B13.681,800Gap DownHigh Trading VolumeLGNDLigand Pharmaceuticals4.2277 of 5 stars$165.86-0.5%$176.50+6.4%+58.2%$3.27B$187.58M-41.4780Positive NewsFOLDAmicus Therapeutics3.8731 of 5 stars$7.98-0.1%$16.00+100.5%-29.3%$2.46B$571.16M-66.49480Positive NewsBCRXBioCryst Pharmaceuticals4.2644 of 5 stars$8.19-1.0%$16.70+103.9%-0.1%$1.74B$450.71M-45.50530Positive NewsMNKDMannKind4.3495 of 5 stars$5.57+0.5%$11.17+100.5%-11.2%$1.70B$285.50M50.64400Positive NewsShort Interest ↓CLDXCelldex Therapeutics2.3896 of 5 stars$23.40+2.3%$46.67+99.4%-44.6%$1.52B$7.02M-7.77150Positive NewsNVAXNovavax4.4807 of 5 stars$7.73-2.2%$14.29+84.8%-41.4%$1.28B$1.08B3.391,990Positive NewsDVAXDynavax Technologies4.4564 of 5 stars$9.70-3.6%$24.33+150.9%-15.8%$1.18B$316.27M-21.09350Positive NewsOPKOPKO Health4.3979 of 5 stars$1.42+5.2%$2.75+93.7%-10.8%$1.07B$713.10M-5.682,997GERNGeron3.1294 of 5 stars$1.37-2.1%$3.79+176.3%-71.8%$893.22M$164.45M-10.5470Positive News Related Companies and Tools Related Companies Alkermes Alternatives Ligand Pharmaceuticals Alternatives Amicus Therapeutics Alternatives BioCryst Pharmaceuticals Alternatives MannKind Alternatives Celldex Therapeutics Alternatives Novavax Alternatives Dynavax Technologies Alternatives OPKO Health Alternatives Geron Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INVA) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innoviva, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Innoviva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
